Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
JACC Asia
; 2(3): 287-293, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-36338417
ATP, adenosine triphosphate; DPP-4, dipeptidyl peptidase-4; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; SGLT2, sodiumglucose cotransporter 2; T2DM, type 2 diabetes mellitus; diabetes; heart failure; sodiumglucose cotransporter 2 inhibitor
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JACC Asia
Year:
2022
Document type:
Article
Affiliation country:
Japan
Country of publication:
United States